Letter: what explains improved survival from statin exposure after liver transplantation? Authors' reply

Aliment Pharmacol Ther. 2022 Nov;56(10):1509-1510. doi: 10.1111/apt.17245.

Authors

Chiara Becchetti¹, Melisa Dirchwolf^{1

2}, Jonas Schropp¹, Annalisa Berzigotti¹, Jaime Bosch¹

Affiliations

¹ Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Liver Unit, Hospital Privado de Rosario, Santa Fe, Argentina.

PMID: 36271472
DOI: 10.1111/apt.17245

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Liver Cirrhosis
Liver Neoplasms*
Liver Transplantation* / adverse effects

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors